Abstract
Background
Edaravone dexborneol has been developed as a novel neuroprotective agent and showed a promising result in treatment of stroke. The current meta-analysis aimed to assess the feasibility and efficacy of the edaravone dexborneol in the treatment of stroke.
Method
We performed a systematic review and meta-analysis of literature in four electronic databases. Binary outcomes were analyzed through the risks ratio (RR) and 95% confidence interval (CI), while the continuous outcomes were analyzed through the standardized mean difference (SMD) and 95% CI. Also, we did a subgroup analysis to show more feasibility and safety dimensions.
Results
Five studies with a total of 2415 patients were included. There were 1119 patients in edaravone dexborneol group and 1216 patients in control group. The 90-mRS 0–1 (RR 1.17 [95% CI 1.09–1.25]; p < 0.0001) and 90-day mRS 0–2 (RR 1.12 [95% CI 1.07–1.18]; p < 0.0001) were statistically significant higher in intervention group compared with control group. There was no significant difference between intervention group and control group concerning 90-day mRS 0–3 (RR 1.03 [95% CI 0.99–1.06]; p = 0.07), 90-day mortality rate (RR 0.71 [95% CI 0.45–1.11]; p = 0.13), serious adverse events (RR 0.91 [95% CI 0.72–1.16]; p = 0.45), and NIHSS score ≤1 at days 14 (RR 0.96; p = 0.69), 30 (RR 1.08; p = 0.18), and 90 (RR 1.06; p = 0.15). No heterogeneity in treatment effect was seen in the analysis, and any potential discrepancies were addressed by sensitivity analysis.
Conclusion
Edaravone dexborneol can be a favorable treatment option for patients with stroke. However, more randomized controlled trials are required to confirm our findings.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
